Your session is about to expire
← Back to Search
Dabrafenib + Trametinib for Thyroid Cancer
Study Summary
This trial is testing whether the combination of dabrafenib and trametinib is more effective than placebo for treating patients with locally advanced or metastatic BRAFV600E mutation-positive, differentiated thyroid carcinoma who are refractory to radioactive iodine and have progressed following prior VEGFR targeted therapy.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have been treated with BRAF or MEK inhibitors before.I am 18 years old or older.My tumor has the BRAFV600E mutation.My thyroid cancer is RET fusion positive.My thyroid cancer does not respond to radioactive iodine treatment.I haven't had cancer treatment with antibodies or chemotherapy in the last 4 weeks.I have a history or risk of eye blood vessel blockage or swelling.My thyroid cancer has spread and was confirmed by lab tests.I haven't had radiation for bone metastasis in the last 2 weeks or any other radiation in the last 4 weeks.I haven't taken any kinase inhibitor drugs in the last 2 weeks.My thyroid cancer is anaplastic or medullary.I need assistance with daily activities due to my health condition.My condition worsened after 1 or 2 treatments targeting VEGFR.You have at least one specific spot that can be measured according to certain guidelines.
- Group 1: Placebo dabrafenib plus placebo trametinib
- Group 2: Dabrafenib plus trametinib
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any unfilled positions in this clinical trial for testing new treatments?
"That is correct. The clinical trial, which was posted on November 15th 2021, is currently looking for participants. The trial is admitting 150 patients at 4 locations."
What is the Dabrafenib research landscape?
"Dabrafenib was first trialled in 2012 by the University of Chicago Medical Center. To date, there have been 86 completed studies with dabrafenib. Right now, there are 99 clinical trials underway, with a large portion of these taking place in London, Alberta."
Does Dabrafenib have any potentially life-threatening side effects?
"Dabrafenib is in Phase 3 of clinical trials, which means that while there is data supporting its efficacy, there is also multiple rounds of data supporting its safety. Our team at Power estimates the safety of Dabrafenib to be a 3 on a scale from 1 to 3."
How many test subjects are being treated with this new medication?
"Yes, as of 10/24/2022, this clinical trial is still looking for 150 patients from 4 different sites. The trial was first posted on 11/15/2021."
Does this study have a lot of participating locations within the state?
"There are 4 clinical sites running this trial presently. They are based in London, Edmonton, Calgary and 4 other locations. If you want to enroll, try and pick the location nearest you to cut down on travel."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How responsive is this trial?
Typically responds via
Most responsive sites:
- Novartis Investigative Site: < 48 hours
Average response time
- < 2 Days
Share this study with friends
Copy Link
Messenger